Skip to content

Incidence of tube feed intolerance in critically ill patients with severe infection

Incidence of enteral feeding intolerance in critically ill patients with septic shock: A prospective observational study - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/06/113173
Enrollment
95
Registered
2026-06-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R031- Nonspecific low blood-pressure reading

Interventions

Intervention1: Nil: Nil

Sponsors

Sanjay Gandhi Postgraduate Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients with septic shock condition for at least 24 hours duration AND receiving enteral nutrition beyond trophic feed via nasogastric or orogastric tube

Exclusion criteria

Exclusion criteria: 1. Active gastrointestinal pathology or expected interventions endoscopic evaluation or suspected bowel obstruction 2. History of gastrointestinal surgery 3. Known history of gastroparesis or chronic intestinal dysmotility disorder 4. Vasopressor support with norepinephrine dose equivalent more than 0.5 microgram per kg per minute 5. Receiving enteral nutrition via nasojejunal, feeding jejunostomy or gastrostomy route 6. Moribund condition with expected survival less than 72 hours, caregivers refused to give consent to participate in the study

Design outcomes

Primary

MeasureTime frame
The incidence of enteral feeding intolerance in both commonly used modality, continuous and bolus enteral feeding, in critically ill patients with septic shockTimepoint: Maximum 5 days or stopping of vasopressor whichever happens first after inclusion in the study.

Secondary

MeasureTime frame
The incidence of individual components of GI symptoms including vomiting, diarrhea, abdominal distension, and elevated gastric residual volumeTimepoint: Maximum 5 days or stopping of vasopressor whichever happens first, after inclusion in the study.

Countries

India

Contacts

Public ContactDr P R R Vaishnavi

Sanjay Gandhi Postgraduate Institute of Medical Sciences

m.gurjar@rediffmail.com5222495403

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026